Logo image of TES.MI

TESMEC SPA (TES.MI) Stock Fundamental Analysis

BIT:TES - IT0004585243 - Common Stock

0.0908 EUR
+0 (+0.89%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TES. TES was compared to 105 industry peers in the Machinery industry. While TES is still in line with the averages on profitability rating, there are concerns on its financial health. TES is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

In the past year TES has reported negative net income.
TES had a positive operating cash flow in the past year.
In multiple years TES reported negative net income over the last 5 years.
TES had a positive operating cash flow in each of the past 5 years.
TES.MI Yearly Net Income VS EBIT VS OCF VS FCFTES.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

1.2 Ratios

The Return On Assets of TES (-1.31%) is worse than 74.29% of its industry peers.
TES has a Return On Equity of -7.83%. This is in the lower half of the industry: TES underperforms 75.24% of its industry peers.
TES has a Return On Invested Capital of 8.13%. This is in the better half of the industry: TES outperforms 67.62% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for TES is below the industry average of 8.67%.
The last Return On Invested Capital (8.13%) for TES is above the 3 year average (5.59%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -1.31%
ROE -7.83%
ROIC 8.13%
ROA(3y)0.01%
ROA(5y)-0.3%
ROE(3y)-0.38%
ROE(5y)-1.87%
ROIC(3y)5.59%
ROIC(5y)N/A
TES.MI Yearly ROA, ROE, ROICTES.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10

1.3 Margins

With a decent Operating Margin value of 8.69%, TES is doing good in the industry, outperforming 70.48% of the companies in the same industry.
TES's Operating Margin has improved in the last couple of years.
TES has a Gross Margin (36.81%) which is comparable to the rest of the industry.
TES's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 8.69%
PM (TTM) N/A
GM 36.81%
OM growth 3Y55.44%
OM growth 5Y15.63%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.55%
GM growth 5Y1.81%
TES.MI Yearly Profit, Operating, Gross MarginsTES.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TES is destroying value.
TES has about the same amout of shares outstanding than it did 1 year ago.
TES has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TES has an improved debt to assets ratio.
TES.MI Yearly Shares OutstandingTES.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
TES.MI Yearly Total Debt VS Total AssetsTES.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.00, we must say that TES is in the distress zone and has some risk of bankruptcy.
TES's Altman-Z score of 1.00 is on the low side compared to the rest of the industry. TES is outperformed by 70.48% of its industry peers.
TES has a Debt/Equity ratio of 1.32. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.32, TES is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF N/A
Altman-Z 1
ROIC/WACC1
WACC8.13%
TES.MI Yearly LT Debt VS Equity VS FCFTES.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

TES has a Current Ratio of 1.19. This is a normal value and indicates that TES is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of TES (1.19) is worse than 75.24% of its industry peers.
TES has a Quick Ratio of 1.19. This is a bad value and indicates that TES is not financially healthy enough and could expect problems in meeting its short term obligations.
TES has a worse Quick ratio (0.59) than 87.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.59
TES.MI Yearly Current Assets VS Current LiabilitesTES.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

4

3. Growth

3.1 Past

TES shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.07%, which is quite impressive.
Looking at the last year, TES shows a decrease in Revenue. The Revenue has decreased by -4.80% in the last year.
The Revenue has been growing slightly by 3.61% on average over the past years.
EPS 1Y (TTM)174.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110.53%
Revenue 1Y (TTM)-4.8%
Revenue growth 3Y7.23%
Revenue growth 5Y3.61%
Sales Q2Q%3.45%

3.2 Future

The Earnings Per Share is expected to grow by 94.37% on average over the next years. This is a very strong growth
TES is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.10% yearly.
EPS Next Y211.11%
EPS Next 2Y94.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1.23%
Revenue Next 2Y4.28%
Revenue Next 3Y4.1%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
TES.MI Yearly Revenue VS EstimatesTES.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
TES.MI Yearly EPS VS EstimatesTES.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2019 2020 2022 2023 2024 2025 2026 0 0.01 0.02 0.03

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Forward Earnings ratio is 5.62, which indicates a rather cheap valuation of TES.
Based on the Price/Forward Earnings ratio, TES is valued cheaply inside the industry as 98.10% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.69. TES is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 5.62
TES.MI Price Earnings VS Forward Price EarningsTES.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

74.29% of the companies in the same industry are more expensive than TES, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.81
TES.MI Per share dataTES.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3

4.3 Compensation for Growth

TES's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TES's earnings are expected to grow with 94.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y94.37%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

TES does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TESMEC SPA

BIT:TES (9/5/2025, 7:00:00 PM)

0.0908

+0 (+0.89%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)08-06 2025-08-06
Earnings (Next)11-07 2025-11-07
Inst Owners0.72%
Inst Owner ChangeN/A
Ins Owners4.78%
Ins Owner ChangeN/A
Market Cap55.07M
Analysts80
Price Target0.08 (-11.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.62
P/S 0.23
P/FCF N/A
P/OCF 7.31
P/B 0.78
P/tB 1.99
EV/EBITDA 5.81
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY17.8%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.01
OCFY13.67%
SpS0.4
BVpS0.12
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.31%
ROE -7.83%
ROCE 10.9%
ROIC 8.13%
ROICexc 9.39%
ROICexgc 12.58%
OM 8.69%
PM (TTM) N/A
GM 36.81%
FCFM N/A
ROA(3y)0.01%
ROA(5y)-0.3%
ROE(3y)-0.38%
ROE(5y)-1.87%
ROIC(3y)5.59%
ROIC(5y)N/A
ROICexc(3y)7.05%
ROICexc(5y)N/A
ROICexgc(3y)9.21%
ROICexgc(5y)N/A
ROCE(3y)7.56%
ROCE(5y)N/A
ROICexcg growth 3Y70.51%
ROICexcg growth 5Y11.87%
ROICexc growth 3Y63.57%
ROICexc growth 5Y10.04%
OM growth 3Y55.44%
OM growth 5Y15.63%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.55%
GM growth 5Y1.81%
F-Score6
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.32
Debt/FCF N/A
Debt/EBITDA 2.28
Cap/Depr 122.3%
Cap/Sales 10.06%
Interest Coverage 1.14
Cash Conversion 18.43%
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 0.59
Altman-Z 1
F-Score6
WACC8.13%
ROIC/WACC1
Cap/Depr(3y)161.13%
Cap/Depr(5y)148.44%
Cap/Sales(3y)14.73%
Cap/Sales(5y)15.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110.53%
EPS Next Y211.11%
EPS Next 2Y94.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.8%
Revenue growth 3Y7.23%
Revenue growth 5Y3.61%
Sales Q2Q%3.45%
Revenue Next Year1.23%
Revenue Next 2Y4.28%
Revenue Next 3Y4.1%
Revenue Next 5YN/A
EBIT growth 1Y71.65%
EBIT growth 3Y66.68%
EBIT growth 5Y19.8%
EBIT Next Year215.71%
EBIT Next 3Y53.8%
EBIT Next 5YN/A
FCF growth 1Y0.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.8%
OCF growth 3Y-16.98%
OCF growth 5YN/A